fbpx
Digital - Business - Media

Part #1 & 2: COO Damon Michaels On Mydecine’s Collaboration With Johns Hopkins University

Last week, Mydecine Innovations Group (NEO: MYCO)(OTCMKTS: MYCOF) inked a five-year agreement with the Johns Hopkins University School of Medicine to study the therapeutic use of psychedelics. The pairing with one of the world’s most prestigious research institutions was a nice addition to Mydecine’s CV, as it continues to cement its research credentials with investors. We invited COO Damon Michaels to the program to opine on this and other company events.

Founded in 1876, the university was named for its first benefactor, the American entrepreneur and philanthropist Johns Hopkins. The Johns Hopkins School of Mydicine is consistently ranked among the top three medical schools in the country and top 25 in the world. The institution operates six academic and community hospitals and four suburban health care and surgery centers. It receives more research grants than almost any school in the world.

Needless to say, partnering with such a revered institution is a significant reputational win for Mydecine Innovations.

Although the immediate research agenda was not disclosed, it was inferred that smoking cessation would be the primary focal point. This would a logical extension to the research it is conducting with compound MYCO-004 for substance use disorder and smoking cessation, announced in June. And that has the potential to branch-off into additional study priorities:

Damon Michaels: It’s been a long time coming. This definitely wasn’t an overnight situation. We’re extremely happy we were finally able to get through all the legal and finally announce to the world that we now are in that partnership agreement with Johns Hopkins University through working with Dr. Matthew Johnson. We knew the indication around smoking cessation, you know, proved incredible efficacy and, of course, safety around utilizing psilocybin for this type of treatment… And obviously it will evolve into, you know, potential off-labels of addiction in general for those types of treatments.

Click on the embedded link for more of our inaugural interview with Mydecine Innovations Chief Operating Officer Damon Michaels, in his own words.

PART 2

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More